Venous thromboembolism

There are 281 papers on venous thromboembolism in aging research: 8 trials and 178 observational studies in people, 2 in animals, 88 reviews. The newest story, Nov 21, 2026: “Steroid-response pattern linked to higher blood-clot risk”.

Disease

281 papers study it65 more mention it180 findings

MeSH

47 new papers in 30 daysSee all 346 papers on venous thromboembolism

At a glance

Human observational studies link venous thromboembolism with higher mortality, including in middle-aged patients with non-small-cell lung cancer. Frailty, accelerated PhenoAge and clonal hematopoiesis are associated with higher thromboembolism risk, while obesity associations differ across populations. Human trials show no clear effect of cocoa extract, multivitamin-multimineral supplementation or vitamin D plus calcium on thromboembolism.

180 findings in 126 papers from 2005 to 2026, 50 of them since April 2026

“the risk of VTE occurrence reduced by 18% (odds ratio [OR], 0.82 [95% CI, 0.80-0.83]) in participants with overweight”
Paradoxical Association of Body Mass Index With Occurrence and Mortality of Venous Thromboembolism in Hospitalized Patients: A National Hospital-Based Cohort AnalysisJournal of the American Heart Association2026doi:10.1161/jaha.125.045575
  • Human trial8
  • Humans178
  • Animals2
  • In silico1

Interventions

21

Testosterone

no changein humans3

3 studies
  1. Testosterone was not clearly linked with venous thromboembolism in humans (men and post-menopausal women not using HRT).

    Humansmen and post-menopausal women not using HRT

  2. Testosterone showed no clear effect on venous thromboembolism in humans (when hypogonadism is correctly diagnosed and managed).

    Reviewwhen hypogonadism is correctly diagnosed and managedmales

  3. Testosterone showed no clear effect on venous thromboembolism in humans (late-onset hypogonadism).

    Reviewlate-onset hypogonadismmales

More on Testosterone

GLP-1 receptor agonists

no changein humans1downin humans1HR 0.65

2 studies
  1. GLP-1 receptor agonists were not clearly linked with venous thromboembolism in humans (Type 2 diabetes and HR+/HER2-negative metastatic breast cancer receiving CDK4/6 inhibitors) (HR 0.65, 95% CI 0.39-1.09).

    HumansType 2 diabetes and HR+/HER2-negative metastatic breast cancer receiving CDK4/6 inhibitors5 yearsfemales

  2. GLP-1 receptor agonists are linked with lower venous thromboembolism in humans (preoperative use before nephrectomy; propensity-matched cohort) (OR 0.62).

    Humanspreoperative use before nephrectomy; propensity-matched cohort90 days

More on GLP-1 receptor agonists

Multivitamin-multimineral supplement

no changein humans1HR 0.89

1 study
  1. Multivitamin-multimineral supplement showed no clear effect on venous thromboembolism in humans (HR 0.89, 95% CI 0.73-1.09).

    Human trial3.5 yearsn = 21,442

  2. Multivitamin-multimineral supplement showed no clear effect on venous thromboembolism in humans (HR 0.89, 95% CI 0.73–1.09).

    Human trial3.5 yearsn = 21,442

More on Multivitamin-multimineral supplement

Cocoa extract

no changein humans1HR 0.88

1 study
  1. Cocoa extract showed no clear effect on venous thromboembolism in humans (HR 0.88, 95% CI 0.72-1.08).

    Human trial3.5 yearsn = 21,442

  2. Cocoa extract showed no clear effect on venous thromboembolism in humans (HR 0.88, 95% CI 0.72–1.08).

    Human trial3.5 yearsn = 21,442

More on Cocoa extract

Lorlatinib

no changein humans1

1 study
  1. Lorlatinib showed no clear effect on venous thromboembolism in humans.

    ReviewALK-positive non-small cell lung cancer; comparison limited by small event counts and differing treatment exposure7 years

More on Lorlatinib

Hormone replacement therapy

no changein humans1HR 1.01

1 study
  1. Hormone replacement therapy was not clearly linked with venous thromboembolism in humans (Free of baseline ASCVD, VTE, and cancer; initiation compared with non-initiation) (Adjusted HR 1.01, 95% CI 0.82–1.24).

    HumansFree of baseline ASCVD, VTE, and cancer; initiation compared with non-initiationPredominantly contemporary oral and transdermal formulationsMean follow-up 12 years; up to 23 yearsfemalesn = 52,330

    Hormone therapy not linked to higher heart risk in 52,330 women

    AHA Scientific Sessions 2026 abstract

More on Hormone replacement therapy

Estrogen hormone replacement therapy

no changein humans1

1 study
  1. Estrogen hormone replacement therapy was not clearly linked with venous thromboembolism in humans (postmenopausal patients undergoing breast surgery and reconstruction).

    Humanspostmenopausal patients undergoing breast surgery and reconstructionsystemicbreast90 days postoperatively

More on Estrogen hormone replacement therapy

Incretin-based therapies

no changein humans1

1 study
  1. Incretin-based therapies showed no clear effect on venous thromboembolism in humans (Recent meta-analyses of randomized trials).

    ReviewRecent meta-analyses of randomized trials

More on Incretin-based therapies

Perioperative hormone replacement therapy continuation

no changein humans1

1 study
  1. Perioperative hormone replacement therapy continuation showed no clear effect on venous thromboembolism in humans (perioperative continuation versus cessation).

    Reviewperioperative continuation versus cessation

More on Perioperative hormone replacement therapy continuation

Statins

no changein humans1

1 study
  1. Statins were not clearly linked with venous thromboembolism in humans after traumatic injury.

    Humansafter traumatic injury

More on Statins

Liraglutide

upin humans1OR 6.15

1 study
  1. Liraglutide increases venous thromboembolism in humans (versus control in Bayesian network meta-analysis of RCTs) (OR 6.15, 95% CrI 0.31 to 34.48).

    Human trialversus control in Bayesian network meta-analysis of RCTs

More on Liraglutide

Vitamin D3 + calcium carbonate

no changein humans1HR 0.92

1 study
  1. Vitamin D3 + calcium carbonate showed no clear effect on venous thromboembolism in humans (secondary analysis of RCT) (320 vs 348 VTE events; HR 0.92, 95 % CI 0.79-1.07).

    Human trialsecondary analysis of RCToral1,000 mg calcium carbonate + 400 IU vitamin D3 per dayaverage of seven yearsfemalesn = 36,282

More on Vitamin D3 + calcium carbonate

All 21

Effects

2

GrimAge

upin humans1OR 1.186

1 study
  1. Venous thromboembolism is linked with higher GrimAge in humans (OR 1.186, 95% CI 1.048-1.341).

    Humans

More on GrimAge

Overall survival

downin humans1HR 2.196

1 study
  1. Venous thromboembolism is linked with lower overall survival in middle-aged NSCLC patients (HR = 2.196, 95% CI: 1.691-2.853).

    Humansin middle-aged NSCLC patients

Upstream

8

Lipoprotein

no changein humans2no changein reviews1HR 0.99

3 studies
  1. Lipoprotein was not clearly linked with venous thromboembolism in humans (High versus low lipoprotein(a) concentrations in Black and White individuals).

    HumansHigh versus low lipoprotein(a) concentrations in Black and White individuals

  2. Lipoprotein showed no clear effect on venous thromboembolism in humans (Cohort studies) (HR 0.99, 95% CI 0.85–1.15).

    ReviewCohort studies

  3. Lipoprotein showed no clear effect on venous thromboembolism (genetic association studies).

    Reviewgenetic association studies

More on Lipoprotein

Loss of X chromosome

no changein humans1

1 study
  1. Loss of X chromosome was not clearly linked with venous thromboembolism in humans (Both overall and large clones (clonal fraction ≥10%)).

    HumansBoth overall and large clones (clonal fraction ≥10%)

    Chromosome changes linked to differing clot risks in people

    AHA Scientific Sessions 2026 abstract

More on Loss of X chromosome

Metabolic signatures

mediatesin humans1

1 study
  1. Metabolic signatures are linked with venous thromboembolism in women (15.2% (95% CI, 6.8-21.9)).

    Humansin womenfemales

More on Metabolic signatures

Metabolic syndrome

no changein humans1HR 1.1

1 study
  1. Metabolic syndrome was not clearly linked with venous thromboembolism in humans (HR 1.10; 95% CI 0.90-1.34).

    Humansmalesn = 12,788

More on Metabolic syndrome

Frailty

mediatesin humans1

1 study
  1. Frailty is linked with venous thromboembolism in humans (cancer-associated VTE) (14%).

    Humanscancer-associated VTE

PhenoAgeAccel

mediatesin humans1

1 study
  1. PhenoAgeAccel is linked with venous thromboembolism in humans (cancer-associated VTE) (approximately 6%).

    Humanscancer-associated VTEn = 394,041

More on PhenoAgeAccel

Lean body mass

no changein silico1OR 1.01

1 study
  1. Lean body mass showed no clear effect on venous thromboembolism in silico (OR = 1.01, 95% CI = 0.87-1.17, p = 0.881).

    In silico

Muscle weakness

no changein silico1OR 0.9

1 study
  1. Muscle weakness showed no clear effect on venous thromboembolism in silico (OR = 0.90, 95% CI = 0.76-1.06, p = 0.217).

    In silico

Associations

100

Hormone replacement therapy

upin humans8downin humans1mixedin humans1mixedin reviews1HR 1.59

11 studies
  1. Hormone replacement therapy is associated with venous thromboembolism in humans (1.8% vs 1.4%; HR 1.59, 95% CI 1.15–2.21).

    Humanspremature menopause; compared with no hormone replacement therapy after propensity score matching10 yearsfemales

    Hormone therapy not linked to fewer deaths after premature menopause

    AHA Scientific Sessions 2026 abstract
  2. Hormone replacement therapy is linked with a higher risk of venous thromboembolism in women with rheumatoid arthritis (aHR 1.92 (95% CI 1.19, 3.12)).

    Humansin women with rheumatoid arthritisfemales

  3. Hormone replacement therapy raises the risk of venous thromboembolism in humans (menopause).

    Reviewmenopauseespecially in the first year

  4. Hormone replacement therapy raises the risk of venous thromboembolism in humans.

    Revieworal

  5. Hormone replacement therapy lowers the risk of venous thromboembolism in humans (menopause hormone therapy).

    Reviewmenopause hormone therapytransdermalfemales

  6. Hormone replacement therapy is associated with venous thromboembolism in humans among multiple VTE risk factors.

    Reviewamong multiple VTE risk factors

  7. Hormone replacement therapy raises the risk of venous thromboembolism in humans (postmenopausal women).

    Reviewpostmenopausal womenfemales

  8. Hormone replacement therapy raises the risk of venous thromboembolism in humans (two- to four-fold increased risk).

    Revieworalfemales

  9. Hormone replacement therapy is associated with venous thromboembolism (risk depends on HRT type and route of administration).

    Reviewrisk depends on HRT type and route of administrationsynthetic and body-identical types

  10. Hormone replacement therapy raises the risk of venous thromboembolism in humans (as reported by the Women's Health Initiative randomised placebo-controlled trial).

    Reviewas reported by the Women's Health Initiative randomised placebo-controlled trialfemales

All 11

More on Hormone replacement therapy

Frailty

upin humans6OR 1.91

6 studies
  1. Frailty is linked with a higher risk of venous thromboembolism in humans (HR 1.63, 95% CI 1.49-1.78).

    Humansn = 315,523

  2. Frailty is linked with a higher risk of venous thromboembolism in humans (fully adjusted) (HR 2.09, 95% CI 1.23-3.55).

    Humansfully adjustedmedian follow-up of 7.2 yearsn = 5,551

  3. Frailty is linked with a higher risk of venous thromboembolism in humans after transsphenoidal surgery for Cushing disease (8% vs 0.5% and 2.7%, P = .04).

    Humansafter transsphenoidal surgery for Cushing disease

  4. Frailty raises the risk of venous thromboembolism in humans (OR 1.91, 95% CI 1.15-3.18).

    Review

  5. Frailty raises the risk of venous thromboembolism in humans.

    Review

  6. Frailty is associated with venous thromboembolism in humans (postoperative).

    Reviewpostoperative

Estrogen

upin humans5HR 1.62

5 studies
  1. Estrogen is associated with venous thromboembolism in humans (British-South Asian women).

    HumansBritish-South Asian womenfemalesn = 20,048

  2. Estrogen raises the risk of venous thromboembolism in humans (hepatic first-pass metabolism).

    Reviewhepatic first-pass metabolismoralfemales

  3. Estrogen raises the risk of venous thromboembolism in humans (HR 1.62, 95% CI 1.41–1.86).

    Revieworalfemales

  4. Estrogen raises the risk of venous thromboembolism in humans.

    Revieworal

  5. Estrogen raises the risk of venous thromboembolism in humans.

    Reviewcombined hormonal contraceptives and menopausal hormone therapies

More on Estrogen

Estradiol

downin humans3upin humans1+0.1%RR 0.59

4 studies
  1. Estradiol is associated with venous thromboembolism in humans (0.054%).

    Humanscombined with micronised progesterone or Mirena coil, with or without transdermal testosteronetransdermal1 yearfemalesn = 13,026

  2. Estradiol lowers the risk of venous thromboembolism in humans (Compared with oral administration) (RR 0.59; 95% CI 0.38-0.91).

    ReviewCompared with oral administrationtransdermalfemales

  3. Estradiol lowers the risk of venous thromboembolism in humans (compared with oral estrogen).

    Reviewcompared with oral estrogentransdermalfemales

  4. Estradiol lowers the risk of venous thromboembolism in humans.

    Reviewtransdermalfemales

More on Estradiol

Statins

downin humans3upin humans1OR 0.209–0.88

4 studies
  1. Statins are associated with venous thromboembolism in humans Following primary shoulder arthroplasty.

    HumansFollowing primary shoulder arthroplasty90 days postoperatively

  2. Statins are linked with a lower risk of venous thromboembolism in high-risk trauma ICU patients (OR 0.209, 95% CI: 0.065-0.670).

    Humansin high-risk trauma ICU patientsn = 509

  3. Statins are linked with a lower risk of venous thromboembolism in adults with multiple myeloma (9.2% vs. 12.0%).

    Humansin adults with multiple myeloma5-year

  4. Statins are linked with a lower risk of venous thromboembolism in humans (OR 0.88 (95% CI 0.84-0.93)).

    Humansfemales

More on Statins

GLP-1 receptor agonists

downin humans3RR 0.772

3 studies
  1. GLP-1 receptor agonists are associated with venous thromboembolism in humans (RR 0.772; 95% CI 0.617–0.967).

    HumansPrescription within 1 year and 1 day before primary total knee arthroplasty; propensity-score-matched comparison

  2. GLP-1 receptor agonists are linked with a lower risk of venous thromboembolism in humans (adults with obesity and autoimmune disease; propensity-matched target trial emulation) (HR 0.83 (95% CI 0.72-0.95)).

    Humansadults with obesity and autoimmune disease; propensity-matched target trial emulation

  3. GLP-1 receptor agonists are associated with venous thromboembolism in humans Following Achilles tendon repair in obese patients (2.6% vs. 6.4%; p = 0.5; not statistically significant).

    HumansFollowing Achilles tendon repair in obese patientsn = 337

More on GLP-1 receptor agonists

Clonal hematopoiesis of indeterminate potential

upin humans3HR 1.17–1.49

3 studies
  1. Clonal hematopoiesis of indeterminate potential is linked with a higher risk of venous thromboembolism in humans (HR 1.49, 95% CI 1.02-2.17).

    Humansmedian 7.1-year follow-upn = 3,980

  2. Clonal hematopoiesis of indeterminate potential is associated with venous thromboembolism in humans (HR 1.17 (95% CI, 1.09-1.3)).

    Humansn = 400,000

  3. Clonal hematopoiesis of indeterminate potential is associated with venous thromboembolism in humans.

    Review

More on Clonal hematopoiesis of indeterminate potential

F2

upin humans1downin humans1OR 0.44–1.921

2 studies
  1. F2 is associated with venous thromboembolism in humans (F2 rs1799963 in FinnGen) (OR 1.921).

    HumansF2 rs1799963 in FinnGen

    DNA variants relevant to menopause show varied health links

    Diagnostics (Basel, Switzerland)
  2. F2 is linked with a lower risk of venous thromboembolism in humans (OR 0.44, 95% CI 0.38-0.51).

    Humans

More on F2

F5

upin humans2OR 2.387

2 studies
  1. F5 is associated with venous thromboembolism in humans (F5 rs6025 in FinnGen) (OR 2.387).

    HumansF5 rs6025 in FinnGen

    DNA variants relevant to menopause show varied health links

    Diagnostics (Basel, Switzerland)
  2. F5 is associated with venous thromboembolism in humans (Factor V Leiden carriers in a British-South Asian cohort).

    HumansFactor V Leiden carriers in a British-South Asian cohortfemalesn = 20,048

More on F5

Combined oral contraceptives

upin humans2

2 studies
  1. Combined oral contraceptives raise the risk of venous thromboembolism in humans.

    Review

  2. Combined oral contraceptives raise the risk of venous thromboembolism in humans.

    Review

More on Combined oral contraceptives

All 100

Trial sponsors

Funding

5 grants since 2018

National Heart, Lung, and Blood Institute$5.2MGouvernement du Canada | Canadian Institutes of Health ResearchCA$21.2K

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Venous thromboembolism is linked with higher mortality, while frailty and accelerated PhenoAge are linked with higher thromboembolism risk in human studies. Obesity associations differ by population: lower risk in at-risk inpatients but higher risk in internal medical inpatients. A human trial finds no clear effect of multivitamin-multimineral supplements or cocoa extract.

  2. Summary rewritten as its findings changed.

    As it read before

    Venous thromboembolism is associated with higher mortality in human cohorts; frailty, PhenoAge acceleration and clonal hematopoiesis of indeterminate potential are linked with higher thromboembolism risk. Obesity is linked with lower risk in at-risk inpatients but higher risk in internal medical inpatients. Human trials show no clear effect of multivitamin-mineral supplements or cocoa extract, or vitamin D3 plus calcium in women.

  3. Summary rewritten as its findings changed.

    As it read before

    Frailty, PhenoAge acceleration and clonal hematopoiesis are associated with higher venous thromboembolism risk in human cohorts. Obesity is linked with higher risk in internal medical inpatients but lower risk in broader at-risk inpatient populations. A human trial shows no clear effect of cocoa extract or multivitamin-multimineral supplementation on venous thromboembolism.

  4. Summary rewritten as its findings changed.

    As it read before

    Human cohorts link frailty, higher PhenoAgeAccel, and clonal hematopoiesis with greater venous thromboembolism risk. Obesity is linked with lower risk among at-risk inpatients but higher risk among internal medical inpatients. Human trials report no clear effect from multivitamin-multimineral supplements or cocoa extract, or from vitamin D3 plus calcium carbonate in women.

  5. Summary rewritten as its findings changed.

    As it read before

    Human cohorts link frailty, PhenoAge acceleration, and clonal hematopoiesis of indeterminate potential with higher venous thromboembolism risk, while greater cardiorespiratory fitness is associated with lower risk. Obesity is linked with lower risk in at-risk inpatients but higher risk in internal medicine inpatients. A human trial reports no clear effect of cocoa extract or multivitamin-multimineral supplementation on venous thromboembolism.

Latest

Dec 2025: 4Jan 2026: 9Feb 2026: 16Mar 2026: 17Apr 2026: 4May 2026: 5Jun 2026: 9Jul 2026: 11Aug 2026: 10Sep 2026: 17Oct 2026: 26Nov 2026: 28156 papers in 12 months
Authorea Preprints

Steroid-response pattern linked to higher blood-clot risk

The pattern appeared in 28.7% of glucocorticoid users and involved reduced clot breakdown and injury to the protective coating inside blood vessels.The pattern appeared in 28.7% of glucocorticoid users and involved reduced clot breakdown and injury to the protective coating inside blood vessels.

Preprint: cohort study of 46,782 peopleBiomarkers
Age and Ageing

Stronger grip linked to lower risk of blood clots in veins

Higher grip strength relative to body weight was linked to 13% lower relative clot risk per standard deviation, a measure of variation in strength.Higher grip strength relative to body weight was linked to 13% lower relative clot risk per standard deviation, a measure of variation in strength.

Cohort · 481,945 peoplePopulations
Diagnostics

DNA variants relevant to menopause show varied health links

An observational genomic analysis linked 25 of 31 menopause-relevant DNA variants to at least one trait, with associations spanning up to 16 traits per variant.An observational genomic analysis linked 25 of 31 menopause-relevant DNA variants to at least one trait, with associations spanning up to 16 traits per variant.

Genetic association studyMenopause
AHA Scientific Sessions 2026 Abstract

Hormone therapy not linked to fewer deaths after premature menopause

Over 10 years, 1.6% of hormone therapy users died versus 1.7% of nonusers; hospitalization, worsening heart failure and blood-clot hazards were higher among users.Over 10 years, 1.6% of hormone therapy users died versus 1.7% of nonusers; hospitalization, worsening heart failure and blood-clot hazards were higher among users.

See all 346 papers on venous thromboembolism